# Uric Acid and Two Answers

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/uric-acid-and-two-answers

> Two studies asked whether these drugs lower uric acid. Both said yes. One found the effect 72.7% explained by weight loss; the other found it independent of weight loss.

## Key points

- Tirzepatide lowered serum urate up to 0.95 mg/dL vs 0.18 on placebo over 72 weeks.
- That trial attributed 72.7% of the effect to weight loss. The real-world study found it independent of weight.
- And they differ fivefold in size: 0.95 vs 0.2 mg/dL.
- Gout is managed to a target below 6.0 mg/dL. That threshold is what makes the size decisive.
- NEITHER study counted a single gout flare. Urate is a surrogate.

Two studies asked whether these drugs lower uric acid. Both said yes. One found the effect was **72.7% explained by weight loss**; the other found it was **independent of weight loss**.[1][2] They also disagree about the size of the effect by a factor of five, and a reader who met either one alone would come away confident about something the other contradicts.

## Why uric acid matters here

Uric acid is the substance that crystallizes in joints to cause gout, and gout is disproportionately common in people carrying excess weight. Treatment is managed to a target: bring serum urate below **6.0 mg/dL** and crystals dissolve rather than form.

Because of that threshold, the size of any reduction is what matters. A fall of a full milligram per deciliter can carry someone across the line. A fall of two-tenths cannot.

## The randomized answer

A post hoc analysis of SURMOUNT-1 tracked serum urate in 2,539 adults with obesity or overweight across 72 weeks of tirzepatide or placebo.[1]

*Change in serum uric acid at week 72.[1]*

| Arm | Change in serum urate |
| --- | --- |
| Tirzepatide 5 mg | −0.69 mg/dL |
| Tirzepatide 10 mg | −0.92 mg/dL |
| Tirzepatide 15 mg | **−0.95 mg/dL** |
| Placebo | −0.18 mg/dL |

All active doses beat placebo at P<.001, and the reduction held regardless of where someone started: it did not matter which quartile of baseline urate they were in (P = .610) or what their BMI was (P = .362). Mediation analysis then attributed **72.7% of the urate reduction to the weight loss itself**.

## The real-world answer

URISEMA looked retrospectively at 236 people with type 2 diabetes prescribed oral semaglutide, with a median age of 64 and a BMI of 33.8.[2]

- **Overall urate fell 0.1 mg/dL at six months**, which was not statistically significant (P = 0.52), and 0.2 mg/dL at twelve months (P = 0.01).
- **In people who started above 6 mg/dL**, reductions were larger: 0.6 and 0.8 mg/dL.
- **The changes were independent of weight loss**, of improved blood sugar control, and of prior GLP-1 or SGLT2 inhibitor use.

> The trial put 72.7% of the urate drop down to weight loss. The real-world cohort found its smaller drop was independent of weight loss.

## How both can be right

They are not the same experiment, and the differences are large enough to explain a lot without anyone being wrong.

*What separates them.*

|   | SURMOUNT-1 post hoc | URISEMA |
| --- | --- | --- |
| Design | Randomized, placebo-controlled | Retrospective, observational |
| Drug | Tirzepatide, injected | Oral semaglutide |
| Population | Obesity or overweight | Type 2 diabetes, median age 64 |
| Weight loss achieved | Up to 20.9% | Not the focus; much smaller |
| Baseline urate | Across all quartiles | Mostly already below target |

The last two rows do most of the work. If weight loss drives urate down, a trial producing 20% weight loss will show a large effect largely explained by weight, while a real-world cohort losing far less will show a small effect that weight cannot explain, because there was not enough weight change to explain it with. Two-thirds of the URISEMA cohort were already under the treatment target before starting.

That reading fits both studies but is established by neither: probably weight-driven at large weight losses, possibly something else at small ones, with no study yet designed to separate them.

## What neither study did

> **Neither counted a single gout flare.** Serum urate is a surrogate. It is the treatment target *because* it predicts attacks, not because the number itself hurts. Nobody in either study was followed for whether they had fewer gout attacks, and the surrogate has never been a guarantee. The general problem is set out in [a biomarker is not an outcome](https://glpwatchdog.org/research/a-biomarker-is-not-an-outcome).

So the supportable claim is narrow: these drugs lower serum uric acid, by an amount that depends heavily on how much weight comes off. Whether that translates into fewer gout attacks has only been checked indirectly. A 2024 pooled analysis of 22 randomized outcome trials of newer diabetes drugs found no significant effect of GLP-1 drugs on the risk of gout, while SGLT2 inhibitors lowered it.[3] That is a test of gout occurring in large trial populations, not of flares in people who already have gout, and the authors of the randomized uric-acid analysis still call for further investigation into a possible role in treating it. If aches rather than gout are the worry, [what the trials counted for joint and back pain](https://glpwatchdog.org/research/glp1-joint-pain-back-pain-and-aches) is covered separately. Whether a lower blood level means fewer uric acid kidney stones has not been tested; see [GLP-1 drugs and kidney stones](https://glpwatchdog.org/research/glp1-and-kidney-stones).

One further caution on URISEMA’s predictors. The two factors it identified (starting at or above 7 mg/dL, and switching from a DPP-4 inhibitor) carry odds ratios of 4.54 and 6.53 with intervals running to 19.25 and 27.32. In 236 retrospective patients, intervals that wide establish a direction and very little else.

## Frequently asked questions

### Do GLP-1 drugs lower uric acid?

Both studies found reductions. In the randomized analysis, tirzepatide lowered serum urate by up to 0.95 mg/dL over 72 weeks against 0.18 on placebo. In a real-world cohort on oral semaglutide, the overall reduction was 0.2 mg/dL at twelve months.

### Why do the two results differ so much?

Different drugs, designs and populations, and very different amounts of weight loss. The trial produced up to 20.9% weight loss; the real-world cohort lost far less, and two-thirds of them were already below the gout treatment target before starting.

### Is the effect caused by weight loss?

The trial's mediation analysis attributed 72.7% of the urate reduction to weight loss. The real-world study found its smaller reduction was independent of weight loss. Both readings fit if the effect is largely weight-driven at large weight losses and something else at small ones, though no study has yet been designed to test that.

### Does this mean these drugs treat gout?

No. Neither study counted a single gout attack. Serum urate is the treatment target because it predicts attacks, and lowering a surrogate is not the same as preventing the disease it stands in for.

### Does the size of the reduction matter clinically?

Considerably. Gout is managed to a target below 6.0 mg/dL. A reduction approaching a full milligram per deciliter can move someone across that line; two-tenths cannot.

## References

1. Sattar N, Scilletta S, Stefanski A, et al. Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial. Annals of the Rheumatic Diseases. 2026. PMID: 41198460. https://pubmed.ncbi.nlm.nih.gov/41198460/
2. Moreno-Pérez O, Tejera-Muñoz A, Carreño-Valdivia R, et al. Impact of oral semaglutide on serum urate levels in people with type 2 diabetes: A retrospective real-world analysis (URISEMA study). Seminars in Arthritis and Rheumatism. 2025. PMID: 40816061. https://pubmed.ncbi.nlm.nih.gov/40816061/
3. Wang A, Shi W, Zhang N, et al. Newer Glucose-Lowering Drugs and Risk of Gout: A Network Meta-Analysis of Randomized Outcomes Trials. Clinical Therapeutics. 2024. PMID: 38796335. https://pubmed.ncbi.nlm.nih.gov/38796335/

---

Cite as: GLP Watchdog, Nora Bissett, "Uric Acid and Two Answers", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/uric-acid-and-two-answers

Canonical HTML page: https://glpwatchdog.org/research/uric-acid-and-two-answers

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
